Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | ACP1 | P24666 | 1/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | PDE5A | O76074 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29887199 | 1.00 | NPC1 (0.59) | NPC1RAB9AMAPK1PDPK1SMN1; SMN2 | |
| SCHEMBL23143288 | 0.85 | SMN1; SMN2 (0.56) | NPC1RAB9APDPK1SMN1; SMN2MAPT | |
| SCHEMBL11859660 | 0.79 | RAB9A (0.50) | NPC1RAB9AMAPK1SMN1; SMN2MAPT | |
| SCHEMBL3652642 | 0.76 | NPC1 (1.00) | NPC1RAB9AMAPK1SMN1; SMN2MAPT | |
| SCHEMBL5118282 | 0.74 | AKT2 (0.50) | MAPK1PDPK1MAPT | |
| SCHEMBL24729180 | 0.74 | RAB9A (0.45) | NPC1RAB9AMAPK1SMN1; SMN2MAPT | |
| Phenazine SCHEMBL18770795 | 0.73 | MAPT (0.73) | NPC1RAB9ASMN1; SMN2MAPTLMNA | |
| SCHEMBL20733792 | 0.73 | RAB9A (0.62) | NPC1RAB9AMAPK1SMN1; SMN2MAPT | |
| SCHEMBL17104884 | 0.72 | RAB9A (0.60) | NPC1RAB9AMAPK1SMN1; SMN2MAPT | |
| SCHEMBL3445210 | 0.71 | SMN1; SMN2 (0.81) | NPC1RAB9AMAPK1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116969901-A | Preparation method of 1,2,4-benzotriazine derivative | 浙江师范大学 | 2023-10-31 | — | — | CN | disclosed |
| CN-114957145-B | 1,2,4-benzotriazine derivative and preparation method thereof | 浙江师范大学 | 2023-07-18 | — | — | CN | disclosed |
| CN-114957145-A | 1,2,4-benzotriazine derivative and preparation method thereof | 浙江师范大学 | 2022-08-30 | — | — | CN | disclosed |
| US-8937175-B2 | Compounds as ligands for transition metal complexes and materials made thereof, and use therefor | OSRAM GMBH (DE) | 2015-01-20 | — | — | US | disclosed |
| US-8937175-B2 | Compounds as ligands for transition metal complexes and materials made thereof, and use therefor | OSRAM GMBH (DE) | 2015-01-20 | — | — | US | disclosed |
| EP-2582684-B1 | NEW COMPOUNDS AS LIGANDS FOR TRANSITION METAL COMPLEXES AND MATERIALS PRODUCED THEREOF AS WELL AS USES THEREOF | OSRAM GMBH (DE) | 2014-07-02 | — | — | EP | disclosed |
| US-20130158262-A1 | Compounds as Ligands for Transition Metal Complexes and Materials Made Thereof, and Use Therefor | OSRAM GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130158262-A1 | Compounds as Ligands for Transition Metal Complexes and Materials Made Thereof, and Use Therefor | OSRAM GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-7645903-B2 | immunoglobulins; affinity chromatography | GE HEALTHCARE BIO-SCIENCES AB (SE) | 2010-01-12 | — | — | US | disclosed |
| US-20090138208-A1 | IMMUNOGLOBULIN G BINDING POCKET | GE HEALTHCARE BIO-SCIENCES AB (SE) | 2009-05-28 | — | — | US | disclosed |
| US-20060014735-A1 | Use of urea variants as affinity ligands | CYTIVA BIOPROCESS R&D AB (SE) | 2006-01-19 | — | — | US | disclosed |
| WO-2004039765-A1 | USE OF UREA VARIANTS AS AFFINITY LIGANDS | AMERSHAM BIOSCIENCES AB (SE) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014735-A1 | Use of urea variants as affinity ligands | IGLV6-57, FCGR2A, FCGR3B | NPC1 974/4885RAB9A 4649/4885MAPK1 3795/4885 |
| US-20130158262-A1 | Compounds as Ligands for Transition Metal Complexes and Materials Made Thereof, and Use Therefor | OR51E2, SLC39A11, WEE1 | NPC1 453/4885RAB9A 2071/4885MAPK1 3089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.